Isaacs A., Lindenmann B.: Virus interference. I. The interferon. Proc R Soc Ser B 147:258, 1957
2.
Balmer CM: Clinical use of biologic response modifiers in cancer treatment: An overview—Part I. The interferons. DICP Ann Pharmacother24:761-768, 1990
3.
Steis RG, Smith JW II, Urba WJ, et al: Resistance to recombinant interferon alfa-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med318:1409-1413, 1988
4.
Krown SE: Interferons and interferon inducers in cancer treatment. Semin Oncol13:207-217, 1986
5.
Houglum JE: Interferon: Mechanisms of action and clinical value. Clin Pharmacol2:20-28, 1983
6.
Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol2:336-352, 1984
7.
Spiegel RJ: Clinical overview of alpha interferons. Cancer59:626-631,1987
8.
Sarna G., Pertchek M., Figlin R., et al: Phase I study of recombinant B ser 17 interferon in the treatment of cancer. Cancer Treat Rep70:1365-1372, 1986
9.
Hu E., Horning SJ: Phase I study of recombinant human interferon beta in patients with advanced cancer. J Biol Response Mod6:121-129, 1987
10.
Quesada JR, Kurzrock R., Sherwin SA, et al: Phase II studies of recombinant human interferon gamma in metastatic renal cell carcinoma. J Biol Response Mod6:20-27, 1987
11.
Ernstoff MS , Trautman T., Davis CA, et al: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol5:1804-1810,1987
12.
Ault BH, Stapleton FB, Gaber L., et al: Acute renal failure during therapy with recombinant human gamma interferon. N Engl J Med319:1397-1400, 1988
Silver RT: Interferon in the treatment of myeloproliferative diseases. Semin Hematol27:6-14, 1990 (suppl 4)
15.
Vadhan-Raj S. , Wong G., Gnecco C., et al: Immunological variables as predictors of prognosis in patients with
16.
Kaposi's sarcoma and the acquired immunodeficiency syndrome. Cancer Res46:417-425, 1986
17.
Berek JS, Hader NF, Lagasse LD, et al: Second-look laparotomy in stage III epithelial ovarian cancer: Clinical variables associated with disease status. Obstet Gynecol64:207-212, 1984
18.
Berek JS, Hacker NJ, Lichtenstein A., et al: Intraperitoneal recombinant α-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: A gynecologic oncology group study . Cancer Res45:4447-4453, 1985
19.
Kinney P., Triozzi P., Young D., et al: Preliminary report of a phase II trial of interferon-beta serine in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol6:86, 1987 (abstr)
20.
Sarna GP, Figlin RA, Pertcheck M.: Phase II study of betaseron (β-ser-17-interferon) as treatment of advanced malignant melanoma. J Biol Response Mod6:375-378, 1987
21.
Lillis PK, Brown T., Beougher K., et al: A phase II trial of recombinant beta interferon (betaseron) in advanced colorectal cancer. Proc Am Soc Clin Oncol6:86, 1987 (abstr)
22.
Yung Wka, Castellanos AM, Van Tassel P, et al: Recombinant interferon beta (ifn-β-ser) given intravenously in patients with recurrent malignant gliomas. Proc Am Soc Clin Oncol7:84,1988 (abstr)
23.
Nirenberg A. , Allen J., Packer R., et al: Phase I/II study of iv recombinant beta-interferon (betaseron) in children with recurrent primary brain tumor (abstract). Proc Am Soc Clin Oncol8:305, 1989 (abstr)
24.
Kaplan EH, Rosen ST, Norris D., et al: Phase II study of recombinant human interferon gamma for the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst82:208-212, 1990
Weisbart RH , Golde DW: Physiology of granulocyte and macrophage colony-stimulating factors in host defense. Hematol Oncol Clin North Am3:401-409,1989
27.
Wallerstein R. , Deisseroth A.: Hematopoietic growth factors in cancer treatment . Princip Pract Oncol4:1-16, 1990
28.
Vadhan-Raj S. , Keating M., LeMaistre A., et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med317:1545-1552, 1987
29.
Estey E., Kurzrock R., Talpaz M., et al: Treatment of myelodysplastic syndromes with GM-CSF + ara-C. Proc Am Soc Clin Oncol9:236a, 1990 (abstr)
30.
Antin JH, Smith BR, Holmes W., et al: Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome . Blood72:705-713, 1988
31.
Ganser A., Volkers B., Greher J., et al: Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes: A phase I/II trial. Blood73:31-37, 1989
32.
Thompson JA , Lee DJ, Kidd P., et al: Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: Toxicity, pharmacokinetics, and hematological effects. J Clin Oncol7:629-637, 1989
33.
Vadhan-Raj S., Broxmeyer HE, Spitzer G., et al: Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome. Blood74:1491-1498, 1989
34.
Glaspy JA, Baldwin CG, Robertson PA, et al: Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med109:789-795, 1988
35.
Muhm M., Andreef M., Geissler K., et al: RhGM-CSF in combination with chemotherapy: A new strategy in the therapy of acute myeloid leukemia. Blood74:117a, 1989 (suppl 1)
36.
Evans C., Rosenfeld CS, Winkelstein'A., et al: Perforation of an unsuspected cecal granulocytic sarcoma during therapy with granulocyte-macrophage colony-stimulating factor. N Engl J Med322:337, 1990
37.
Antman KS, Griffin JD, Elias A., et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med319:593-598,1988
38.
Gabrilove JL , Jakubowski A., Scher H., et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med318:1414-1422, 1988
39.
Bronchud MH , Scarffe JH, Thatcher N., et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer56:809-813, 198739. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation . N Engl J Med318:869-876, 1988
40.
Nemunaitis J., Singer JW, Buckner CD, et al: Use of recombinant human granulocyte-macrophage colony-stimulating factor: A phase I-II trial . Ann Intern Med110:976-984,1989
41.
Peters WP, Kurtzberg J., Atwater S., et al: Comparative effects of rHuG-CSF and rHuGM-CSF on hematopoietic reconstitution and granulocyte function following chemotherapy and autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol8:181, 1989 (abstr 702)
42.
Sheridan W. , Morstyn G., Green M., et al: Phase II study of granulocyte colony-stimulating factor (G-CSF) in autologous bone marrow transplantation (ABMT). Proc Am Soc Clin Oncol8:178, 1989 (abstr 691)
43.
Peters WP, Kurtzberg J., Kirkpatrick G., et al: GM-CSF primed peripheral blood progenitor cells coupled with autologous bone marrow transplantation will eliminate leukopenia following high dose chemotherapy. Blood74: 50a, 1989 (suppl 1)
44.
Gianni AM, Bregni M., Stern AC, et al: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet2:580-585, 1989
45.
Ventura CJ, Spitzer G., Hester J., et al: A controlled trial of mobilized peripheral blood progenitor cells: Does their addition to autologous bone marrow transplant and growth factor cause faster hematopoietic recovery?Proc Am Soc Clin Oncol9:9, 1990 (abstr)
46.
Nemunaitis J., Singer JW, Buckner CD, et al: The use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure following bone marrow transplantation . Blood76:245-253, 1990
47.
Antin JH, Smith BR, Holmes W., et al: Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome . Blood72:705-713, 1988
48.
Champlin RE , Nimer SD, Ireland P., et al: Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony-stimulating factor. Blood73:694-699,1989
49.
Shimosaka A. , Ogawa M., Masaoka T., et al: Clinical development of recombinant human G-CSF in Japan. Overview. Mol Biother1, 1989 (abstr 19) (suppl)
50.
Vadhan-Raj S., Buescher S., Broxmeyer HE, et al: Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage colony-stimulating factor. N Engl J Med319:1628-1634, 1988
51.
Bonilla MA, Gilioi AP, Ruggerio M., et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on neutropenia in patients with congenital granulocytopenia. N Engl J Med320:1574-1580,1989
52.
Hammond WP, Price TH, Souza LM, et al: Treatment of cyclinc neutropenia with granulocyte-macrophage colony-stimulating factor. N Engl J Med320:1306-1311, 1989
53.
Jakubowski AA, Souza L., Kelly F., et al: Effects of human granulocyte-macrophage colony-stimulating factor in a patient with idiopathic neutropenia. N Engl J Med320:38-42, 1989
54.
Groopman JE , Mitsuyasu RT, DeLeo MJ, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med317:593-598, 1987
55.
GlaspyJ., Moreno J., Mitsuyasu R., et al: Recombinant granulocyte-macrophage colony-stimulating factor (r-met HUG), recombinant erythropoietin (r-HuEPO) and zidovudine (AZT) in patients with AIDS complicated by anemia and neotropenia. Mol Biother1, 1989 (abstr 17) (suppl)
56.
Erard F., Corthesy P, Nabholzm, et al: Interleukin-2 is both necessary and sufficient for the growth and differentiation of lectin-stimulated cytolytic T lymphocyte precursors . J Immunol134:1644-1652, 1985
57.
Henney CS, Kuribayashi K., Kern DE, et al: Interleukin-2 augments natural killer cell activity. Nature291:335-358, 1981
58.
Shaw Are, Blackley RC, Merryweather JP, et al: Modulation of human natural killer cell activity by recombinant human interleukin-2. Cell Immunol91:193-200, 1985
59.
Rosenberg SA , Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients . Ann Surg210:474-485, 1989
60.
Smith KA: Interleukin-2: Inception, impact, and implications. Science240:1169-1176, 1988
61.
Sosman JA, Hank JA, Sondel PM: In vivo activation of lymphokine-activated killer activity with interleukin-2: Prospects for combination therapies. Semin Oncol17:22-30, 1990 (suppl 1)
62.
Stotter H., Wiebke EA, Tomita S., et al: Cytokines alter target cell susceptibility to lysis. J Immunol142:1767-1773, 1989
63.
Pennica D., Nedwin GE, Hayflick JS, et al: Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature312:724-729, 1984
64.
Herberman RB : Interleukin-2 therapy of human cancer: Potential benefits versus toxicity. J Clin Onco17:1-4, 1989
65.
Rosenberg SA , Lotze MT, Muul LM, et al: Progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med316:889-897, 1987
66.
Rosenberg SA , Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med313:1485-1492, 1985
67.
Margolin KA , Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines . J Clin Oncol7:486-498,1989
68.
Kohler G., Milstein C.: Continuous culture of fused cells secreting antibody of predefined specificity . Nature256:495-497, 1975
69.
Haspel MV, McCabe RP, Pomato N., et al: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal cancer patient. Cancer Res45:3951-3961, 1985
70.
Liu AY, Robinson RR, Hellström KE, et al: Chimeric mouse-human IgG, antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci84:3439-3443, 1987
71.
Hamblin TJ, Cattan AR, Glennie MJ, et al: Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody. Blood69:790-797,1987
72.
Gringauz AM : Monoclonal antibodies and the war against cancer . US Pharm60-67,1987
73.
Tami JA, Parr MD, Brown SA, et al: Monoclonal antibody technology. Am J Hosp Pharm43:2816-2825, 1986
74.
Dillman RO: Monoclonal antibodies for treating cancer. Ann Intern Med111:592-603,1989
75.
Houghton A. , Scheinberg D.: Monoclonal antibodies in the treatment of hemetologic malignancies. Semin Hematol25:23-29, 1988
76.
Granger SW, Janossy G., Francis G., et al: Elimination of T-lymphocytes from human bone marrow with monoclonal antibodies and cytolytic complement. Br J Haematol50:367-374, 1982
77.
Prentice HG , Blacklock HA, Janossy G., et al: Depletion of T-lymphocytes in donor marrow prevents significant graft versus host disease in matched allogeneic leukemic marrow transplants. Lancet1:472-476, 1984
78.
Posner MR, Calabresi P.: Immunotherapy for cancer— Current progress, future promise. Hosp Ther53-65, 1987
79.
Jansen J., Falkenburg Jhf, Stepan DE, et al: Removal of neoplastic cells from autologous bone marrow grafts with monoclonal antibodies. Semin Hematol21:164-181, 1984
80.
Gilewski TA , Golomb HM: Design of combination biotherapy studies: Future goals and challenges. Semin Oncol17:3-10, 1990 (suppl 1)
